What is Suboxone and how does it treat opioid use disorder?
Suboxone is a sublingual film or tablet that combines buprenorphine, a partial mu-opioid agonist, with naloxone, an opioid antagonist that deters injection misuse. Buprenorphine occupies opioid receptors with high affinity but only partial activation, which suppresses cravings and withdrawal without producing the euphoria or respiratory depression of full agonists like heroin or fentanyl.
The FDA approved buprenorphine/naloxone for office-based treatment of opioid use disorder in 2002 under the Drug Addiction Treatment Act. NIDA-funded research shows that buprenorphine cuts opioid overdose mortality by more than 50% when prescribed at adequate doses and continued long enough for stabilization.
Suboxone is one of three FDA-approved medications for opioid use disorder, alongside methadone and naltrexone. SAMHSA classifies all three as first-line evidence-based treatments in TIP 63.
How does Suboxone induction work in PHP and IOP?
Induction is the first phase of Suboxone treatment, beginning only when the client is in moderate withdrawal — typically a COWS (Clinical Opiate Withdrawal Scale) score of 8 or higher. Starting Suboxone too early, while a full opioid agonist is still occupying receptors, displaces that agonist and precipitates acute withdrawal.
Ascend's medical team begins induction with 2–4 mg of buprenorphine sublingually, observes the client for 60–90 minutes, and titrates upward as withdrawal symptoms resolve. Most clients reach a stable dose of 8–16 mg per day within 72 hours.
- PHP induction: Daily medical monitoring, COWS scoring, and dose adjustment alongside group and individual therapy.
- IOP transition: Once stable, clients step down to less frequent medical visits while continuing structured therapy.
- Co-occurring care: Psychiatric evaluation, CBT, and trauma therapy run in parallel with medical induction.
Questions About How does Suboxone induction?
Call our 24/7 admissions line or verify your insurance online.
Who is appropriate for Suboxone treatment?
Suboxone is appropriate for adults with a DSM-5 diagnosis of moderate-to-severe opioid use disorder who can tolerate partial agonist therapy and are willing to engage in behavioral treatment. SAMHSA recommends buprenorphine as a first-line option for most patients with opioid use disorder, including those using fentanyl, heroin, or prescription opioids.
Clinical indications for Suboxone over other MAT options include a history of unsuccessful detox attempts, polysubstance use complicating methadone dosing, pregnancy (SAMHSA recommends continued buprenorphine through pregnancy), and a preference for office-based rather than daily-dosed care.
Contraindications are narrow: severe hepatic impairment, hypersensitivity to buprenorphine or naloxone, and certain drug interactions. Ascend's medical team conducts a full evaluation before induction.
“Buprenorphine is medicine. It normalizes the brain chemistry disrupted by chronic opioid use, removes the daily survival mode of chasing a dose, and gives clients the cognitive bandwidth to do the therapy work that sustains long-term recovery.”
How long should I stay on Suboxone?
SAMHSA TIP 63 and NIDA both recommend a minimum of 12 months on buprenorphine, with many patients benefiting from multi-year or indefinite maintenance. Studies show that retention on Suboxone at 6 months exceeds 75% in structured programs, and longer retention correlates with lower overdose mortality, reduced illicit opioid use, and improved employment and housing outcomes.
Premature tapering — particularly within the first 6 months — significantly increases the risk of relapse and fatal overdose, because tolerance drops while environmental triggers persist. The decision to taper is individualized and made collaboratively between the client and the medical team based on clinical stability, support systems, and stress load.
At Ascend, tapering protocols typically span 6–12 months once a client elects to discontinue, with close monitoring throughout.